Investigation and analysis of single nucleotide polymorphisms in Janus kinase/signal transducer and activator of transcription genes with leukemia

References

• Darnell JE, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994;264:1415–1421.
   PubMed Web of Science ®Google Scholar
• Haura EB, Turkson J, Jove R. Mechanisms of disease: insights into the emerging role of signal transducers and activators of transcription in cancer. Nat Clin Pract Oncol 2005;6:315–324.
   Google Scholar
• Nieborowska-Skorska M, Wasik MA, Slupianek A, . Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Srh homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesis. J Exp Med 1999; 189:1229–1242.
   PubMed Web of Science ®Google Scholar
• de Groot RP, Raaijmakers JA, Lammers JW, . STAT5 activation by BCR-Abl contributes to transformation of K562 leukemia cells. Blood 1999;94:1108–1112.
   PubMed Web of Science ®Google Scholar
• Lacronique V, Boureux A, Valle VD, . A TEL JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 1997;278:1309–1312.
   PubMed Web of Science ®Google Scholar
• Peeters P, Raynaud SD, Cools J, . Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor- associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood 1997;90:2535–2540.
   PubMed Web of Science ®Google Scholar
• Hoefsloot LH, van Amelsvoort MP, Broeders LC, . Erythropoietin-induced activation of STAT5 is impaired in the myelodysplastic syndrome. Blood 1997;89:1690–1700.
   PubMed Web of Science ®Google Scholar
• Tabrizi M, Yang W, Jiao H, . Reduced Tyk2/SHP-1 interaction and lack of SHP-1 mutation in a kindred of familial hemophagocytic lymphohistiocytosis. Leukemia 1998;12:200–206.
   PubMed Web of Science ®Google Scholar
• Balmain A, Gray J, Ponde B. The genetics and genomics of cancer. Nat Genet 2003;33:238–244.
   PubMed Web of Science ®Google Scholar
• Zhong Y, Chen B, Feng J, . The associations of Janus kinase-2 (JAK2) A830G polymorphism and the treatment outcomes in patients with acute myeloid leukemia. Leuk Lymphoma 2010;51:1115–1120.
   PubMed Web of Science ®Google Scholar
• Poncz M, Solowiejczyk D, Harpel B, . Construction of human gene libraries from small amounts of peripheral blood: analysis of beta-like globin genes. Hemoglobin 1982;6:27–36.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Lasho TL, Patnaik MM, . JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival. Leukemia 2010;24: 105–109.
   PubMed Web of Science ®Google Scholar
• James C, Ugo V, Le Couédic JP, . A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144–1148.
   PubMed Web of Science ®Google Scholar
• Baxter EJ, Scott LM, Campbell PJ, . Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054–1061.
   PubMed Web of Science ®Google Scholar
• Kratz CP, Boll S, Kontny U, . Mutational screen reveals a novel JAK2 mutation, L611S, in a child with acute lymphoblastic leukemia. Leukemia 2006;20:381–383.
   PubMed Web of Science ®Google Scholar
• Lee JW, Kim YG, Soung YH, . The JAK2 V617F mutation in de novo acute myelogenous leukemias. Oncogene 2006;25:1434–1436.
   PubMed Web of Science ®Google Scholar
• Zhang SJ, Li JY, Li WD, . The investigation of JAK2 mutation in Chinese myeloproliferative diseases-identification of a novel C616Y point mutation in a PV patient. Clin Lab Haematol 2007;29:71–72.
   Google Scholar
• Schnittger S, Bacher U, Kern W, . Report on two novel nucleotide exchanges in the JAK2 pseudokinase domain: D620E and E627E. Leukemia 2006;20:2195–2197.
   PubMed Web of Science ®Google Scholar
• Malinge S, Ben AR, Settegrana C, . A novel activating JAK2 mutation in a patient with Down syndrome and precursor B-cell acute lymphoblastic leukemia. Blood 2007;109:2202–2204.
   PubMed Web of Science ®Google Scholar
• Butcher CM, Hahn U, To LB, . Two novel JAK2 exon 12 mutations in JAK2V617F-negative polycythaemia vera patients. Leukemia 2008;22:870–873.
   PubMed Web of Science ®Google Scholar
• Mercher T, Wernig G, Moore SA, . JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model. Blood 2006;108:2770–2779.
   PubMed Web of Science ®Google Scholar
• Pich A, Riera L, Sismondi F, . JAK2V617F activating mutation is associated with the myeloproliferative type of chronic myelomonocytic leukaemia. J Clin Pathol 2009;62:798–801.
   PubMed Web of Science ®Google Scholar
• Pardanani A, Lasho TL, Finke CM, . The JAK2 46/1 haplotype confers susceptibility to essential thrombocythemia regardless of JAK2V617F mutational status—clinical correlates in a study of 226 consecutive patients. Leukemia 2010;24:110–114.
   PubMed Web of Science ®Google Scholar
• Jones AV, Chase A, Silver RT, . JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat Genet 2009;41:446–449.
   PubMed Web of Science ®Google Scholar
• Animesh, Brooke L, Terra L, . Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders. Blood 2008;111:2785–2789.
   PubMed Web of Science ®Google Scholar
• Calo V, Migliavacca M, Bazan V, . STAT proteins: from normal control of cellular events to tumorigenesis. Cell Physiol 2003;197: 157–168.
   Web of Science ®Google Scholar
• Ward AC, Hermans MHA, Smith L, . Tyrosine-dependent and independent mechanisms of STAT3 activation by the human granulocyte colony-stimulating factor (G-CSF) receptor are differentially utilized depending on G-CSF concentration. Blood 1999;93:113–124.
   PubMed Web of Science ®Google Scholar
• Hermans MHA, Ward AC, Antonissen C, . Perturbed granulopoiesis in mice with a targeted mutation in the granulocyte colony-stimulating factor receptor gene associated with severe chronic neutropenia. Blood 1998;92:32–39.
   PubMed Web of Science ®Google Scholar
• Hermans MHA, Antonissen C, Ward AC, . Sustained receptor activation and hyperproliferation in response to granulocyte colony-stimulating factor (G-CSF) in mice with a severe congenital neutropenia/acute myeloid leukemia-derived mutation in the G-CSF receptor gene. J Exp Med 1999;189:683–692.
   PubMed Web of Science ®Google Scholar
• Ward AC, van Aesch YM, Schelen AM, . Defective internalization and sustained activation of truncated granulocyte colony-stimulating factor receptor found in severe congenital neutropenia/acute myeloid leukemia. Blood 1999;93:447–458.
   PubMed Web of Science ®Google Scholar
• Ilaria RL Jr, Van Etten RA. P210 and P190 (BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J Biol Chem 1996;271:31704–31710.
   PubMed Web of Science ®Google Scholar
• Van Etten RA. Aberrant cytokine signaling in leukemia. Oncogene 2007;26:6738–6749.
   PubMed Web of Science ®Google Scholar
• Wernig G, Mercher T, Okabe R, . Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 2006;107:4274–4281.
   PubMed Web of Science ®Google Scholar
• Spiekermann K, Biethohn S, Wilde S, . Constitutive activation of STAT transcription factors in acute myelogenous leukemia. Eur J Haematol 2001;67:63–71.
   PubMed Web of Science ®Google Scholar
• Sebastian K, Katherine W, Rudiger H, . Polymorphic variation at the STAT5 locus is associated with the response of CML patients to interferon alpha. Blood 2007;110(Suppl. 1): Abstract 2913.
   Google Scholar
• Onishi M, Nosaka T, Misawa K, . Identification and characterization of a constitutively active STAT5 mutant that promotes cell proliferation. Mol Cell Biol 1998;18:3871–3879.
   PubMed Web of Science ®Google Scholar